Trial Profile

A Phase 1 Study of ANV419 as Monotherapy, and ANV419 in Combination With Daratumumab or With Lenalidomide Plus Low-Dose Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma (OMNIA-2)

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ANV 419 (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Hyaluronidase
Indications Multiple myeloma
Focus Adverse reactions
Acronyms OMNIA-2
Sponsors Anaveon

17 Aug 2023 Status changed from recruiting to discontinued.
06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
16 Mar 2023 According to a Anaveon media release, company expects to report initial data of this trial in early 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com